Safety and effectiveness of a synthetic hemostatic patch for intraoperative soft tissue bleeding

Christoph Schuhmacher,1 Johann Pratschke,2 Sascha Weiss,2 Stefan Schneeberger,2 André L Mihaljevic,1 Rebekka Schirren,1 Michael Winkler,3 Nikos Emmanouilidis3 1Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 2Department...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Schuhmacher C, Pratschke J, Weiss S, Schneeberger S, Mihaljevic AL, Schirren R, Winkler M, Emmanouilidis N
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/38891819ebb8467087904e841576c7df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Christoph Schuhmacher,1 Johann Pratschke,2 Sascha Weiss,2 Stefan Schneeberger,2 André L Mihaljevic,1 Rebekka Schirren,1 Michael Winkler,3 Nikos Emmanouilidis3 1Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; 2Department of Visceral, Transplant, and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria; 3Department of General, Visceral, and Transplantation Surgery, Hannover Medical School, Hannover, Germany Background: Continuous bleeding after using conventional hemostatic methods involving energy, sutures, or clips, is a serious and costly surgical complication. Many topical agents have been developed to promote intraoperative hemostasis, but improvement is needed in both decreasing time to hemostasis and increasing ease of use. Veriset™ hemostatic patch is CE-marked for controlling bleeding on the liver and in soft tissue. In the current study, we aimed to gather further evidence for the safety and effectiveness of Veriset™ hemostatic patch in soft tissue bleeding during a variety of surgical procedures. Methods: Thirty patients scheduled for nonemergency surgery, each with an intraoperative soft tissue bleeding site, were treated with Veriset™ hemostatic patch. Time to hemostasis was monitored, and adverse events were assessed during the 90 days after surgery. Results: When Veriset™ hemostatic patch was used, hemostasis occurred within 5 minutes in 29/30 (96.7%) subjects and within 1 minute in 21/30 (70.0%) subjects. No device-related serious adverse events were recorded during the 30 days after surgery, and no reoperations for device-related bleeding complications were performed during the 5 days after surgery. Conclusions: Veriset™ hemostatic patch is a safe and effective hemostat for controlling soft tissue bleeding during a variety of surgical procedures. Keywords: Veriset™ hemostatic patch, hemostasis, topical hemostat